| Identification | Back Directory | [Name]
1H-Imidazo[4,5-c]pyridine, 1-[4-[[3-[(1E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]phenyl]methoxy]phenyl]-2-methyl- | [CAS]
139401-43-7 | [Synonyms]
CP 96021
1H-Imidazo[4,5-c]pyridine, 1-[4-[[3-[(1E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]phenyl]methoxy]phenyl]-2-methyl- | [Molecular Formula]
C29H21FN4OS | [MOL File]
139401-43-7.mol | [Molecular Weight]
492.57 |
| Chemical Properties | Back Directory | [Boiling point ]
727.0±70.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
6.29±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma[1]. | [IC 50]
LTD4: 34±5 nM (Ki) | [References]
[1] Marfat A, et al. The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists[J]. Bioorganic & Medicinal Chemistry Letters, 1995, 5(13): 1377-1382. |
|
|